Juvenile Inflammatory Rheumatism (JIR) Cohorte
- Conditions
- Arthritis, Juvenile Rheumatoid
- Registration Number
- NCT02377245
- Lead Sponsor
- Michaël Hofer
- Brief Summary
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.
- Detailed Description
The JIR-cohort has to be filled by an authorized investigator during or after the consultation. Each patient much be followed at least once a year.
Different data are requested in the JIR-cohort: diagnosis, treatment, adverse events and outcome.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 15000
- Patients with juvenile inflammatory diseases
- Age at onset up to 18 years old
- Consent according national codes of ethics and current laws
- Non-consent from patients and/or legal representative
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of severe and very severe adverse event as a mesure of safety and tolerability 10 years Number of treatments prescribed off label 10 Years Length in months of drug survival in patient treated with at least two consecutive biological agents 10 Years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (45)
Hôpital Reine Fabiola
🇧🇪Bruxelles, Belgium
CHU Charleroi
🇧🇪Charleroi, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
CHC Liège
🇧🇪Liège, Belgium
CHR Citadelle
🇧🇪Liège, Belgium
CHU Belfort
🇫🇷Belfort, France
CHRU Besançon
🇫🇷Besançon, France
Hôpital Pellegrin enfants
🇫🇷Bordeaux, France
CHRU Brest
🇫🇷Brest, France
Hôpital Femme Mère Enfant
🇫🇷Bron, France
Scroll for more (35 remaining)Hôpital Reine Fabiola🇧🇪Bruxelles, Belgium